This site is intended for Healthcare Professionals only.

Pakistan’s drug regulatory agency approves phase-3 trial for a Chinese-made coronavirus vaccine

Date:

Share post:

Pakistan’s drug regulatory agency has approved final-phase testing of a Chinese-made vaccine against Covid-19.

In a statement on Monday (Aug 17), the state-run National Institute of Health said the approval to carry out advanced clinical trials for potential Covid-19 was granted by Drug Regulatory Authority of Pakistan.

It said the phase-3 clinical trials for a candidate vaccine against the new virus will be conducted at the country’s main health facilities.

It said the vaccine was produced by CanSinoBio, a China-based vaccine developer and Beijing Institute of Biotechnology.

Pakistan, which has witnessed a steady decline in fatalities from the new virus, reported only 15 new Covid-19 deaths and 617 new cases in the past 24 hours. It has reported 289,832 cases since February when the first infection was detected in the country. (AP)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Opioid overdose: Pharmacy professionals to be able to supply naloxone without a prescription

DHSC also publishes a new 10-year strategic plan to expand and improve the drug and alcohol workforce The...

New NHS patient choice scheme offers 5 options, but nursing shortages persist

Royal College of Nursing CE urges caution amidst new NHS patient choice pilot scheme rollout "Patients deserve choice, but...

Prof Ryan Donnelly awarded prestigious RPS Harrison Memorial Medal 2024

RPS HMM winner Professor Donnelly's work has secured £30M+ funding through his pioneering work in developing advanced polymeric...

Pharmacies forced to subsidise NHS medicines: NPA hands £108m invoice to DHSC

The NPA calls for a new deal that reverses “historical funding cuts and gives the sector the respect...